Target intelligence / Profile preview

Nuclear fragile X mental retardation-interacting protein 2 (NUFIP2)

Target
NUFIP2
Molecular classification
RNA-binding protein, Other (does not fit canonical receptor, enzyme, transporter, etc.)
01

Overview

Nuclear fragile X mental retardation-interacting protein 2 (NUFIP2) is a ubiquitously expressed, non-canonical RNA-binding protein that interacts strongly with Roquin family proteins and is involved in post-transcriptional regulation of specific mRNA species, such as those encoding the T cell costimulatory molecule ICOS and the receptor OX40[1][3][4][5][6]. NUFIP2 localizes to cytoplasmic stress granules, nuclear bodies, and ribosomes, and its interaction with Roquin proteins enhances recognition and regulation of certain mRNA targets involved in immune cell function[1][2][3][4]. NUFIP2 also interacts with the fragile X mental retardation protein (FMRP), and competition between FMRP and Roquin for NUFIP2 likely influences mRNA decay pathways[1][3]. While associated genetically with neurodevelopmental and brain malformation syndromes, NUFIP2 is not recognized as a classical therapeutic target, nor are there approved drugs targeting its activity[4][5][6].

Other names
FMR1-interacting protein NUFIP2KIAA1321PIG182-FIPMGC117262182-FIPFIP-82NUFP2Cell proliferation-inducing gene 1 proteinFMRP-interacting protein 2Nuclear FMR1-interacting protein 282 kDa FMRP-interacting protein82-kD FMRP Interacting ProteinProliferation-inducing gene 1
02

Mechanism of action

None reported for direct drug targeting

03

Biological functions

Association with RNA granules and stress granulesRNA binding activityCofactor in post-transcriptional regulation, especially mRNA decayInteraction with Roquin family proteins to regulate immune cell-related mRNA stability
04

Disease associations

Associated with Fragile X syndromeAssociated with Bilateral Perisylvian PolymicrogyriaOther (no established direct roles in cancer, inflammation, etc.)

Beyond the preview

Go deeper on Nuclear fragile X mental retardation-interacting protein 2 (NUFIP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear fragile X mental retardation-interacting protein 2 (NUFIP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call